View all cases
UPC APP 8340/2025
—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- Status—ActionProcedural applicationCategoryOther Procedural
- Parties
- Division
- Court of Appeal
- Judges
- Rian Kalden · Presiding judge and judge-rapporteur
- Patricia Rombach · Legally qualified judge
- Ingeborg Simonsson · Legally qualified judge
- Technology
- Organic Chemistry
- Language
- —
- First decided
- Jun 19, 2025
Decisions
- 2025-06-19DismissedAppeal decisionGeneric application
Court of Appeal Panel 2 rejected Alexion Pharmaceuticals' application for rehearing (R. 245 RoP) of the earlier Court of Appeal order dismissing Alexion's appeal against the Hamburg Local Division's denial of provisional measures. Alexion had alleged fundamental procedural defects (new claim interpretation standard applied without being heard, and incorrect facts). The Court held that no fundamental procedural defect within the meaning of Art. 81(1)(b) UPCA / R. 247(c) RoP was established. Alexion ordered to bear Samsung's costs of the rehearing proceedings.
Legal issues:Rehearing application (Art. 81(1)(b) UPCA, R. 245 RoP)Fundamental procedural defectRight to be heard (Art. 76 UPCA)Paroxysmal nocturnal hemoglobinuria treatment / complement inhibitor
Documents
- A513FE13383EB02063F5F132D98F814C_en.pdf2025-06-19ENGLISH